Key Summary
- The World Health Organization (WHO) and the FDA have issued warnings following a massive spike in falsified obesity drugs across the authorized supply chain.
- High prices, lack of insurance, and the intense desire for weight loss are pushing patients toward unregulated online sales and border pharmacies.
- Counterfeit injectables often lack active ingredients or contain toxic substances, leading to life-threatening complications such as hyperglycaemia and cardiovascular issues.
A report published in The Lancet journal reveals that fake and falsified obesity drugs are creating a significant public health crisis.
High costs and a lack of insurance coverage are driving patients toward counterfeit versions of popular brand-name "GLP-1 receptor agonists" like Ozempic and Mounjaro.
These medications are designed to manage diabetes and obesity by targeting appetite, but their surge in popularity has opened the door for unprecedented levels of fraud.
Shabbir Safdar, executive director of the Partnership for Safe Medicines, stated that he has seen more fraud surrounding weight-loss injectables than at any other point in his career.
Counterfeits with fake labels and boxes are being sold in vacation areas in Mexico and at pharmacies on the U.S. border, making it nearly impossible for consumers to distinguish between real and re-wrapped products.
WHO has detected falsified products in almost 60 countries, noting that the trend continues to intensify due to self-diagnosis, self-prescription practices, and unregulated online sales.
Research published in the Journal of Medicine, Surgery and Public Health warns that these fakes often contain incorrect dosages or entirely different, harmful ingredients. This can lead to ineffective treatment or life-threatening cardiovascular and metabolic complications.
A WHO spokesperson emphasized that the transition to tablet forms of these drugs may make it even easier for falsifiers to produce them at a larger scale.
Beyond the immediate physical dangers, experts are concerned about the social implications of the drug rollout. Professor Alexandra Brewis of Arizona State University noted that the high cost and difficulty of accessing these medications could worsen the stigma surrounding obesity.
Authorities reiterate that GLP-1 products should only be used under the direction of a healthcare professional to ensure appropriate dosing and necessary clinical follow-up.
